329 related articles for article (PubMed ID: 20308469)
1. Correction to the relative risk calculation for gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis.
Jain R; Levine M
Radiology; 2010 Apr; 255(1):307-8; author reply 308. PubMed ID: 20308469
[No Abstract] [Full Text] [Related]
2. Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function?
Lind Ramskov K; Thomsen HS
Acta Radiol; 2009 Nov; 50(9):965-7. PubMed ID: 19863403
[No Abstract] [Full Text] [Related]
3. Gadolinium and nephrogenic systemic fibrosis.
Runge VM
AJR Am J Roentgenol; 2009 Apr; 192(4):W195-6; discussion W197. PubMed ID: 19304681
[No Abstract] [Full Text] [Related]
4. Can gadolinium be given safely to a patient on dialysis?
Rodby RA
Semin Dial; 2011; 24(4):370-1. PubMed ID: 21801214
[No Abstract] [Full Text] [Related]
5. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network.
Stratta P; Canavese C; Quaglia M; Fenoglio R
Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228
[No Abstract] [Full Text] [Related]
6. Focus on contrast-associated nephrogenic systemic fibrosis.
Partain CL
J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
[No Abstract] [Full Text] [Related]
7. Special issue: nephrogenic systemic fibrosis.
Leiner T; Kucharczyk W
J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
[No Abstract] [Full Text] [Related]
8. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
Abraham JL; Edward M
AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
[No Abstract] [Full Text] [Related]
9. Nephrogenic systemic fibrosis: is gadolinium to be blamed?
Jikki PN
J Assoc Physicians India; 2008 Nov; 56():915-6. PubMed ID: 19263697
[No Abstract] [Full Text] [Related]
10. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
Dawson P
J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621
[No Abstract] [Full Text] [Related]
11. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
[TBL] [Abstract][Full Text] [Related]
12. Gadolinium and systemic fibrosis: guilt by association.
Kay J; Czirják L
Ann Rheum Dis; 2010 Nov; 69(11):1895-7. PubMed ID: 20959325
[No Abstract] [Full Text] [Related]
13. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor.
Lu CF; Hsiao CH; Tjiu JW
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):339-40. PubMed ID: 18573157
[No Abstract] [Full Text] [Related]
14. Nephrogenic systemic fibrosis: the need for accurate case reporting.
Spinazzi A; Kirchin MA; Pirovano G
J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
[No Abstract] [Full Text] [Related]
15. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
Wang SC
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
[No Abstract] [Full Text] [Related]
16. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic systemic fibrosis.
Weinreb JC; Kuo PH
Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
[TBL] [Abstract][Full Text] [Related]
18. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
[No Abstract] [Full Text] [Related]
19. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
Martin DR
Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788
[No Abstract] [Full Text] [Related]
20. Gadolinium-induced NSF claim resolved in favor of plaintiff.
Ball JB; Samaritan G
J Med Assoc Ga; 2012; 101(3):32-3. PubMed ID: 23198628
[No Abstract] [Full Text] [Related]
[Next] [New Search]
